These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 15382217

  • 1. Selection of candidates with HCC for transplantation in the MELD era.
    Sala M, Varela M, Bruix J.
    Liver Transpl; 2004 Oct; 10(10 Suppl 2):S4-9. PubMed ID: 15382217
    [Abstract] [Full Text] [Related]

  • 2. Overview of the MELD/PELD system of liver allocation indications for liver transplantation in the MELD era: evidence-based patient selection.
    Freeman RB.
    Liver Transpl; 2004 Oct; 10(10 Suppl 2):S2-3. PubMed ID: 15382218
    [No Abstract] [Full Text] [Related]

  • 3. [The value of MELD in the allocation of priority for liver transplantation candidates].
    Colmenero J, Castro-Narro G, Navasa M.
    Gastroenterol Hepatol; 2010 Apr; 33(4):330-6. PubMed ID: 19631411
    [Abstract] [Full Text] [Related]

  • 4. Selection of pediatric candidates under the PELD system.
    McDiarmid SV, Merion RM, Dykstra DM, Harper AM.
    Liver Transpl; 2004 Oct; 10(10 Suppl 2):S23-30. PubMed ID: 15384170
    [Abstract] [Full Text] [Related]

  • 5. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
    Piscaglia F, Camaggi V, Ravaioli M, Grazi GL, Zanello M, Leoni S, Ballardini G, Cavrini G, Pinna AD, Bolondi L.
    Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
    [Abstract] [Full Text] [Related]

  • 6. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH.
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [Abstract] [Full Text] [Related]

  • 7. Liver transplant recipient selection: MELD vs. clinical judgment.
    Fink MA, Angus PW, Gow PJ, Berry SR, Wang BZ, Muralidharan V, Christophi C, Jones RM.
    Liver Transpl; 2005 Jun; 11(6):621-6. PubMed ID: 15915491
    [Abstract] [Full Text] [Related]

  • 8. When is a patient too well and when is a patient too sick for a liver transplant?
    Merion RM.
    Liver Transpl; 2004 Oct; 10(10 Suppl 2):S69-73. PubMed ID: 15382215
    [Abstract] [Full Text] [Related]

  • 9. A new liver transplant priority for patients with hepatocellular carcinoma.
    Ravaioli M, Grazi GL, Vetrone G, Kimura T, Zanello M, Ercolani G, Cescon M, Varotti G, Del Gaudio M, Tuci F, Cucchetti A, La Barba G, Vivarelli M, Lauro A, Ramacciato G, Pinna AD.
    Hepatogastroenterology; 2008 Oct; 55(86-87):1742-5. PubMed ID: 19102382
    [Abstract] [Full Text] [Related]

  • 10. Current controversies surrounding liver transplantation for hepatocellular carcinoma.
    Silva MF, Wigg AJ.
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1217-26. PubMed ID: 20594247
    [Abstract] [Full Text] [Related]

  • 11. Is hepatic transplantation justified for primary liver cancer?
    Fisher RA, Maluf DG, Wolfe L, Williams B, Cotterell A, Stravitz RT, Heuman D, Posner M.
    J Surg Oncol; 2007 Jun 15; 95(8):674-9. PubMed ID: 17477383
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
    Toso C, Dupuis-Lozeron E, Majno P, Berney T, Kneteman NM, Perneger T, Morel P, Mentha G, Combescure C.
    Hepatology; 2012 Jul 15; 56(1):149-56. PubMed ID: 22271250
    [Abstract] [Full Text] [Related]

  • 17. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
    Kemmer N, Neff G, Kaiser T, Zacharias V, Thomas M, Tevar A, Satwah S, Shukla R, Buell J.
    Liver Transpl; 2006 Oct 15; 12(10):1519-22. PubMed ID: 17004260
    [Abstract] [Full Text] [Related]

  • 18. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
    Murillas J, Rimola A, Laguno M, de Lazzari E, Rascón J, Agüero F, Blanco JL, Moitinho E, Moreno A, Miró JM, ESLD-HIV Working Group Investigators.
    Liver Transpl; 2009 Sep 15; 15(9):1133-41. PubMed ID: 19718643
    [Abstract] [Full Text] [Related]

  • 19. Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy.
    Huo TI, Huang YH, Su CW, Lin HC, Chiang JH, Chiou YY, Huo SC, Lee PC, Lee SD.
    Clin Transplant; 2008 Sep 15; 22(4):469-75. PubMed ID: 18318736
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.